NCT04401813CompletedPhase 1
Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
An Open-label, Single-arm, Phase Ib Study of the Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 97 (actual)
- First submitted
- 6 May 2020
- Start date
- Jun 2020
- Primary completion date
- Jun 2024
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04401813
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 97
- From Jun 2020 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history of hepatic encephalopathy, or have a history of liver transplantation.
- Diffuse liver cancer.
Other
- Histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components.
Who the study is looking for
- Locally advanced or metastatic hepatocellular carcinoma, confirmed by histology/cytology.
- Disease progression after surgery and / or local treatment.
- Previous standard systemic treatments for advanced hepatocellular carcinoma have failed or developed intolerable toxicity.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital Affiliated to Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.